CryptoMedix is focused on advancing immuno-oncology therapies that target the tumor microenvironment (TME). Their innovative technology platform includes first-in-class therapeutic antibodies designed to enhance the function of cytotoxic T-cells, which are crucial for attacking tumor cells, while simultaneously inhibiting tumor-suppressive macrophages within the TME. Notably, their lead compounds, CMX-101 and CMX-102, exhibit a unique mechanism of action that synergizes with PD(L)1 immune-checkpoint inhibitors through proteasome-mediated degradation of the PDL1 protein. This approach has led to the issuance of two new U.S. patents, highlighting the potential of their therapies to improve patient outcomes in oncology, particularly for those who do not respond well to existing PD(L)1 inhibitors.

In addition to their primary focus on PD(L)1 inhibitors, CryptoMedix's therapeutic antibodies also interact with other immune checkpoints, such as LAG-3, thereby broadening their immuno-oncology applications. CMX-102, in particular, has garnered significant interest due to its stationary nature within the TME, making it a promising candidate for use as antibody-drug conjugates (ADCs) or in combination with radionuclides. This specificity for the TME, coupled with its intrinsic anti-tumor activity, positions CMX-102 as more than just a delivery mechanism for cytotoxic agents. However, it is important to note that these antibodies are still in the early pre-clinical stages of development, and the company is actively seeking partnerships and funding to advance their research and clinical applications.

United States

CryptoMedix is a biotech company in the field of Oncology, developing highly innovative treatments for cancer.

CryptoMedix

Company Details